Abstract | Amyotrophic lateral sclerosis (ALS) is a genetically diverse disease. At least 15 ALS-associated gene loci have so far been identified, and the causative gene is known in approximately 30% of familial ALS cases. Less is known about the factors underlying the sporadic form of the disease. The molecular mechanisms of motor neuron degeneration are best understood in the subtype of disease caused by mutations in superoxide dismutase 1, with a current consensus that motor neuron injury is caused by a complex interplay between multiple pathogenic processes. A key recent finding is that mutated TAR DNA-binding protein 43 is a major constituent of the ubiquitinated protein inclusions in ALS, providing a possible link between the genetic mutation and the cellular pathology. New insights have also indicated the importance of dysregulated glial cell-motor neuron crosstalk, and have highlighted the vulnerability of the distal axonal compartment early in the disease course. In addition, recent studies have suggested that disordered RNA processing is likely to represent a major contributing factor to motor neuron disease. Ongoing research on the cellular pathways highlighted in this Review is predicted to open the door to new therapeutic interventions to slow disease progression in ALS.
Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of devastating impact that causes injury and death of lower motor neurons in the brainstem and spinal cord, and of upper motor neurons in the motor cortex. The resulting progressive failure of the neuro muscular system usually culminates in death from respiratory failure. The worldwide incidence of approximately two per 100,000 individuals is fairly uniform, except for a few high-incidence foci, such as the Kii peninsula and Guam. The mean age of onset is 55-60 years, and the disease more commonly affects men than women. The average survival from symptom onset is approximately 3 years, although a proportion of patients have a slower disease course. 1 ALS was traditionally considered to be a pure motor disorder. However, recent findings in subsets of patients with ALS have highlighted the involvement of sensory and spinocerebellar pathways, as well neuronal groups within the substantia nigra and the hippocampal dentate granule layer. 2 ALS is, therefore, regarded as a multisystem disorder in which the motor neurons tend to be affected earliest and most severely. The major gross and microscopic pathological changes are highlighted in Box 1.
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The pathogenic processes underlying ALS are multifactorial and, at present, not fully determined. This Review discusses recent advances in our understanding of the neurodegenerative process, relating predominantly to the subtype of disease caused by mutations in the gene encoding superoxide dismutase 1 (SOD1). Newly identified genes associated with ALS have important roles in RNA processing, endosomal trafficking and protein degradation pathways. We highlight the complex interplay between multiple mechanisms, including genetic factors, oxidative stress, excitotoxicity and protein aggregation, as well as impairments in RNA processing, axonal transport and mitochondrial function ( Figure 1 ). We also discuss the increasingly recognized role of neighboring glial cells in motor neuron injury, 10 the involvement of particular molecular signaling pathways in motor neuron survival and cell death, [11] [12] [13] [14] and the emerging concept that the neuro muscular junction and distal axonal compartment are early and important aspects of disease pathophysiology. 15 Finally, we consider why motor neurons are particularly susceptible to cell death in ALS, and suggest links between cellular pathogenic pathways and key clinical features of the disease.
Mouse models of ALS harboring mutant SOD1 (mSOD1 models), discussed in this article, have been used extensively for preclinical drug testing, with many therapies reported to ameliorate the disease course. However, the utility of these mouse models for the develop ment of human therapies has been questioned owing to poor results in clinical trials (Box 2).
are applicable not only to the minority of cases that carry familial ALS (FALS) mutations, but also to sporadic ALS (SALS) more broadly.
The FALS-associated gene variants so far identified (Table 1) have provided important clues about the underlying molecular mechanisms in the disease, as discussed below. In addition, candidate gene analysis in patients with SALS has identified polymorphisms in the genes encoding vascular endothelial growth factor, hereditary hemochromatosis protein and paraxonase enzymes PON1-3, as well as copy number variation in the survival motor neuron genes SMN1 and SMN2, as potential risk factors for ALS. 18 These findings have not, however, been consistently replicated in different populations. Similarly, recent genome-wide association studies have identified several potential ALS susceptibility loci, including FGGY, 19 inositol 1,4,5-trisphosphate receptor type 2 (ITPR2) 20 and dipeptidyl-peptidase 6 (DPP6). 21 These results have yet to be validated in additional independent populations. In 2010, two separate groups reported the association of SALS with single nucleotide poly morphisms on chromosome 9p21, 22, 23 which is also an identified susceptibility locus for FALS and frontotemporal dementia 24 (see Note added in proof ). Intermediate-length polyglutamine expansions in ataxin-2 have recently been identified as a risk factor for sporadic ALS. 25 A detailed discussion of genetic factors in ALS is beyond the scope of this article and has been reviewed elsewhere. 26 Oxidative stress Oxidative stress causes structural damage and changes in redox-sensitive signaling. It arises from an imbalance between the generation and removal of reactive oxygen species (ROS), and/or from a reduction in the ability of the biological system to remove or repair ROS-induced damage. The accumulation of oxidative stress in nonreplicating neurons during aging may be an important factor that tips the balance from an ability to cope with a toxic insult, such as the presence of a disease-causing mutation, into a vicious circle of cellular injury that culminates in neuronal death and onset of neuro degeneration in middle or later life. Particular interest has been shown in the role of oxidative stress in ALS, because mutations in SOD1, which encodes a major antioxidant protein, account for 20% of FALS cases. 27 Biosamples from patients with ALS-including cerebro spinal fluid (CSF), serum and urine-show elevation of markers of free radical damage. [28] [29] [30] More over, elevated levels of oxidative damage to proteins, 31 lipids 32 and DNA 33 have been found in postmortem tissue from SALS and SOD1-related FALS cases. Oxidative damage to RNA species has also been documented in mSOD1 mouse models as well as the human CNS. 34 In the murine model, mRNA oxidation is primarily found in motor neurons and oligodendrocytes, occurs in the early presymptomatic disease stages, and is associated with decreased expression of the encoded proteins. Some mRNA species seem to be more susceptible to oxidation, including those involved in the mitochondrial electron transport chain, protein biosynthesis, folding and degrada tion pathways, myelination, the cytoskeleton, and the tricarboxylic acid cycle and glycolysis pathways. 34 Oxidative damage occurs in cellular and murine models of SOD1-related ALS (reviewed elsewhere 35 ) and, interestingly, the SOD1 protein itself seems to be particularly susceptible to oxidative post-translational modification. 36 Recently developed cellular models of mutant TAR DNA-binding protein 43 (TDP-43)-related ALS indicate that the presence of this mutant protein also induces oxidative stress in motor neuronal cell lines. 37 Sources of oxidative stress in ALS have been mostthoroughly investigated in mSOD1 models, in which activation of several aberrant oxidative reactions have been proposed (as reviewed previously 35 ). However, mutant SOD1 that is enzymatically inactive due to depletion of copper loading is still capable of causing motor neuron degeneration, 38 and recent evidence suggests that mSOD1 may cause oxidative stress by mechanisms beyond its catalytic activity. Specifically, mSOD1 in microglia increases NADPH oxidase (NOX)-mediated superoxide production by locking Rac1 into its active state in the NOX complex, resulting in prolongation of ROS production. 39 NOX2 expression is increased in mSOD1 mice and in the CNS of patients with ALS, and survival of SOD1 G93A mice is extended by knockout of Nox1 or Nox2. 40, 41 The transcription factor nuclear erythroid 2-related factor 2 (NRF2) is a master regulator of the antioxidant response. This factor binds and upregulates antioxidant response element (ARE) genes following oxidative stress. Recent evidence has emerged that NRF2-ARE signaling may be dysregulated in mSOD1 models of ALS, 11 and in the CNS of patients with ALS. 42 Multiple studies have shown that oxidative stress inter acts with, and potentially exacerbates, other pathophysiological processes that contribute to motor neuron injury, including excitotoxicity, 43 mitochondrial impairment, 44 protein aggregation, 45 endoplasmic reticulum (ER) stress, 46 and alterations in signaling from astrocytes and microglia. 47, 48 Thus, effective alleviation of oxidative stress could potentially ameliorate multiple facets of the pathobiology of motor neuron degeneration. A metaanalysis of therapeutic interventions tested in mSOD1 mice up to 2007 concluded that antioxidant therapies were the most effective class of drug at improving survival. 49 Antioxidants have not yet shown benefit in patients with ALS, although the reported trials have often been of suboptimal design. 50 
Mitochondrial dysfunction
Mitochondria have a central role in intracellular energy production, calcium homeostasis and control of apoptosis. Several lines of evidence implicate mitochondrial dysfunction in ALS pathogenesis (Figure 2 ). In mSOD1 mice, the mutated protein aggregates in vacuoles in the mitochondrial intermembrane space, 51 and shows an age-dependent increase in adherence to the mitochondrial outer membrane, which is postulated to lead to organelle dysfunction selectively in the spinal cord by impeding protein import. [52] [53] [54] Defective respiratory chain function associated with oxidative damage to mitochondrial proteins and lipids has been found in tissue from patients with ALS 55 and in mSOD1 models. 56 Thus, dysregulated energy metabolism is likely to contribute to motor neuron dysfunction in ALS.
Calcium buffering is impaired in mitochondria purified from the CNS of mSOD1 mice, 57 and could increase the susceptibility of motor neurons to the altered calcium homeostasis associated with glutamate-mediated excitoxicity (discussed below). Furthermore, ER stress, which is predicted to disrupt ER-mitochondria calcium exchange, has been reported in models of ALS. 58 Motor neuron cell death in ALS is thought to involve the activation of caspases and apoptosis, and damage to mito chondrial function is likely to contribute to this process. 59 Altered mitochondrial morphology has been observed in skeletal muscle and spinal motor neurons from patients with ALS. 60 Interestingly, in some mSOD1 mouse models, mitochondrial vacuolation occurs during the presymptomatic disease stage, suggesting an early event in the pathophysiological cascade of motor neuron injury. 51 Mitochondrial morphology is also altered in primary motor neurons and NSC-34 cells (a murine motor neuronal cell line) expressing mutant SOD1. 61 Axonal transport of mitochondria is impaired in experimental models of ALS, and it is possible that a reduction in the mitochondrial content of the distal axon, combined with impaired mitochondrial function, leads to the dying-back axonopathy that is seen in ALS. 62, 63 Mitochondria represent an attractive target for ALS therapy development, and the novel mitochondrion-targeted neuro protective compound olexisome 64 is currently in a phase III clinical trial for ALS.
Excitotoxicity
Glutamate is the main excitatory neurotransmitter in the CNS and exerts its effects through an array of ionotropic and metabotropic postsynaptic receptors. The excitatory signal is terminated by removal of glutamate from the synaptic cleft by glutamate reuptake trans porters, the most abundant of which is excitatory amino acid transporter 2 (EAAT2; also known as SLC1A2 or GLT1). Excitotoxicity, the neuronal injury resulting from excessive activation of glutamate receptors, may be caused by increased synaptic levels of glutamate, or by increased sensitivity of the postsynaptic neuron to glutamate, resulting from alterations in neuronal energy homeostasis or glutamate receptor expression. 65 Disruption of intracellular calcium homeostasis, with secondary activation of proteolytic and ROS-generating enzyme systems, and perturbation of mitochondrial function and ATP production are key components of excitotoxicity. 66 α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors mediate much of the routine fast excitatory glutamatergic neurotransmission in the CNS. Motor neurons are especially vulnerable to AMPAmediated excitotoxicity, including distal axonal injury. 67, 68 The calcium permeability of the AMPA receptor complex is largely determined by the GluR2 subunit, which is post-transcriptionally edited at the Gln/Arg site 586 in the second transmembrane domain, making the receptor complex calcium-impermeable. 69 Cell-specific features of motor neurons, including low expression of both GluR2 69 and calcium-buffering proteins, 70 render these neurons vulnerable to AMPA receptor-mediated toxicity.
A body of evidence implicates excitotoxicity as a mechanism contributing to motor neuron injury in ALS, although clear evidence that it is a primary disease mechanism is lacking. In some patients with ALS, levels of CSF glutamate are elevated, 71 and the expression and activity of EAAT2 are reduced in pathologically affected areas of the CNS, [72] [73] [74] although whether this is a cause or a consequence of neuronal loss is unclear. 75 Electrophysiological studies in humans have shown hyperexcitability of the motor system in the presymptomatic 76 or early stages 77 of ALS. Evidence suggests that the calcium permeability of AMPA receptors in the spinal ventral horn may be dysregulated by abnormal editing of the GluR2 AMPA receptor subunit. 78 In addition, a recently identified ALSlinked gene encodes d-amino acid oxidase (DAO). This enzyme is responsible for the oxidative deamination of d-amino acids, one of which-d-serine-is an activator and co-agonist of N-methyl-d-aspartate (NMDA) receptors. 79 Mutations in DAO could potentially contribute to excitotoxic motor neuron injury.
Several findings in the mSOD1 model also point towards a role for excitotoxicity in ALS pathology, including altered electrophysiological properties and increased sensitivity of motor neurons to excitotoxicity, 80 altered AMPA receptor subunit expression, reduced expression Box 2 | The mutant SOD1 mouse model Many therapies have been reported to ameliorate disease in the mouse model of amyotrophic lateral sclerosis (ALS) that harbors mutant superoxide dismutase 1 (SOD1). However, the utility of this mouse model for the development of human therapies has been questioned owing to poor results in clinical trials. 16, 17 Many interventions reported as positive have shown mild effects on the disease course, which might simply represent 'biological noise' in the mouse model. An important concept in preclinical trials in mouse models that requires clarification is the definition of 'onset' and 'progression' of disease. A current challenge lies in distinguishing which therapies are truly delaying the onset of disease versus prolonging the compensatory preclinical period, in which the disease process is ongoing in the absence of clinical signs of motor dysfunction. In mutant SOD1 mice, various abnormalities are present well before the onset of clinical signs, often in the first few postnatal days. These abnormalities include behavioral motor changes, 187 motor neuron electrophysiological abnormalities, 188, 189 neuropathological changes such as mitochondrial swelling and vacuolization, 190 and transcriptome changes reflecting an attempt to increase energy provision in motor neurons. 131 A recently described mutant SOD1 zebrafish model shows evidence of chronic neuronal stress from early embryogenesis. 191 The zebrafish model has several strengths that complement murine models of ALS. For example, this model is relatively inexpensive and is useful for high-throughput screening to identify pharmacological and genetic modifiers of disease phenotype. The transparency of the zebrafish embryos is advantageous for the imaging of motor neurons in an in vivo system. and activity of EAAT2, 81 increased glutamate efflux from spinal cord nerve terminals, 82 a reduction in the motor neuron inhibitory-excitatory synaptic ratio, 83 and loss of regulation by astrocytes of the expression of GluR2 by neighboring motor neurons. 84 Ameliorating excitotoxicity is the only strategy that has so far slowed disease progression in ALS. Riluzole, which has several effects including inhibition of presynaptic glutamate release, 85 causes a modest increase in survival. 86 However, other antiglutamate agents including gabapentin, lamotrigine, topiramate and talampanel have not been effective in clinical trials. 87 The reasons for this are uncertain, although a possible explanation is that riluzole has multiple potential neuroprotective effects, some of which extend beyond modification of glutamate excitatory neurotransmission. 85 Protein aggregation Pathological protein aggregates, identified as compact or skein-like ubiquitinated inclusions, are a cardinal feature of ALS. [4] [5] [6] The identification of TDP-43 as the major protein constituent of these inclusions initiated a major shift in our understanding of the pathobiology of ALS. 7 Under normal conditions, TDP-43 is predominantly localized in the nucleus, and loss of nuclear TDP-43 staining is seen in most cells containing TDP-43-positive cytoplasmic inclusions. 7 TDP-43 inclusions are not restricted to motor neurons, and it seems that cytoplasmic redistribution of TDP-43 is an early pathogenic event in ALS. 88 In 2008, mutations in TARDBP, the gene encoding TDP-43, were discovered in several FALS pedigrees, thereby consolidating the evidence for TDP-43 dysfunction in ALS and establishing this protein as a crucial player in both sporadic and familial disease. 89 Neurofilament-rich hyaline conglomerate inclusions are observed in the perikaryon or proximal dendrites of spinal cord motor neurons in some ALS cases, particularly those with SOD1 mutations. 5 Increased expression of phosphorylated neurofilament epitopes in the cell body of motor neurons is also seen. 90 Altered stoichi ometry and phosphorylation of neurofilaments may have a critical effect on the functioning of the axonal compartment of the motor neuron. Small eosinophilic Bunina bodies containing cystatin C are seen in motor neurons in up to 85% of cases, 6, 91 although the significance of these inclusions remains uncertain.
SOD1 inclusions are found in motor neurons of patients with FALS, as well as in mouse and cellular models expressing SOD1 mutations. 92 Monoclonal antibodies that are specific for epitopes of misfolded SOD1 strongly label inclusions in motor neurons of patients with SOD1 FALS, 93 and seem to label similar structures in some patients with SALS. 94 Similarly, cytoplasmic inclusions containing mutant fused in sarcoma (FUS) protein have been observed in some patients with FUS-related FALS. 95, 96 Proteins found in aggregates in ALS provide several important clues about the disease pathogenesis. Loss of nuclear TDP-43 and/or aggregation of the protein in cytoplasmic inclusions may be key pathogenic processes in both SALS and FALS. The neurofilamentous pathology suggests that neurofilament dysfunction is important in some forms of ALS. The increase in phosphorylated neurofilament epitopes in motor neuron perikarya may contribute to the observed slowing of axonal neurofilament transport. 97, 98 Other genetic variants provide further evidence that dysregulated protein processing contributes to the pathophysiology of ALS. Exome sequencing identified missense mutations in the valosin-containing protein (VCP) gene in five patients with FALS. 99 VCP is an evolu tionarily conserved AAA+ ATPase that is important in multiple biological processes including cell signaling, protein homeostasis, organelle biogenesis and autophagy 100 through its role in identifying ubiquitinated proteins in multimeric complexes and mediating their proteasomal degradation. Mutations in ubiquilin 2 (UBQLN2), which encodes a cytosolic ubiquitin-like protein, have recently been found to be associated with a dominantly inherited X-linked subtype of ALS. 101 The identified missense mutations lead to impairment of the protein degradation pathway in a cellular model.
Dysregulated endosomal trafficking
Endocytosis is the process by which extracellular molecules are captured at the cell surface membrane and taken into the cell. The cargo is then delivered to its final destination via a complex organelle system termed the endosomal network. Dysregulation of this system decrease in the activity of the complexes that form the mitochondrial electron transport chain, which may be caused by oligomers of mSOD1 associating with mitochondria. These oligomers could to lead to alterations in the mitochondrial redox state, damage to the mitochondrial protein import machinery, and sequestration of the antiapoptotic factor Bcl-2. Loss of EAAT2, and increased expression of calcium-permeable AMPA receptors lacking the edited form of the GluR2 subunit, leads to elevated intracellular calcium in motor neurons. High intracellular calcium concentrations may result in a toxic shift of calcium from the endoplasmic reticulum to the mitochondria, leading to excitotoxicity. Defective electron transport chain activity and calcium homeostasis are thought to underlie aberrant ROS generation. b | Together, these pathways result in depolarization of the mitochondrial membrane potential, reduced production of ATP, increased peroxidation of mitochondrial membrane lipids, opening of the MPTP channel, and initiation of apoptosis with release of cytochrome c into the cytoplasmic compartment. Abbreviations: ALS, amyotrophic lateral sclerosis; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid; EAAT2, excitatory amino acid transporter 2; MPTP, mitochondrial permeability transition pore; mSOD1, mutated superoxide dismutase 1; ROS, reactive oxygen species.
has been implicated in several genetic subtypes of ALS. Mutations in the alsin gene are associated with a form of autosomal recessive juvenile-onset ALS (ALS2). 102 Alsin is a guanine nucleotide exchange factor for the small GTPase protein Rab5 and is involved in endosomal fusion and trafficking, as well as neurite outgrowth. 103 In cellular models, loss of alsin function causes a reduction in endosomal mobility, increased conversion of endosomes to lysosomes, and increased degradation of cargoes such as internalized glutamate receptors. 103 Rare ALS-associated mutations further implicate dys regulated endosomal trafficking as an important patho physiological mechanism. These mutations occur in the following genes: vesicle associated membrane protein-associated protein B (VAPB), 104 optineurin, 105 a component of the endosomal sorting complex required for transport (ESCRTIII), charged multi vesicular protein 2B (CHMP2B), 106, 107 and VCP (described above), which forms a complex with the endocytotic protein clath rin. 99, 100 Heterozygous mutations in the FIG4 gene have been found in a few FALS pedi grees.
108 FIG4 encodes polyphosphoinositide phosphatase, which con trols the cel lular abundance of phosphatidylinositol 3,5-bisphosphate, a signaling lipid that mediates retrograde trafficking of endosomal vesicles to the Golgi apparatus. 109 Whether the deleterious variants of FIG4 have a dominant-negative effect or cause a partial loss of function remains unclear. Motor neurons may be particularly susceptible to disruptions in this network because their long axonal processes result in a high demand for turnover of membrane components.
Impaired axonal transport
Axonal pathology is a key feature of ALS, and might, therefore, have a crucial role in the pathophysiology of the disease. Motor neurons are highly polarized cells with long axons, and axonal transport is required for delivery of essential components-such as RNA, proteins and organelles-to the axonal compartment, which includes synaptic structures at the neuro muscular junction (NMJ). The principal machinery for axonal transport uses microtubule-dependent kinesin and cytoplasmic dynein molecu lar motors, which mediate transport towards the NMJ (anterograde transport) and towards the cell body (retrograde transport), respectively. In mSOD1 mice, defective axonal transport occurs early in the disease process, 62, [110] [111] [112] supporting the hypothesis that dysregulation of axonal transport and the axonal compartment play a part in the pathophysiology of ALS. Mutant SOD1 impairs both anterograde and retrograde trans port of several cargoes. The defects seem to be cargo-specific, as only anterograde transport of mitochondria is disrupted. 62, [110] [111] [112] The mechanisms underlying defective axonal transport in mSOD1 models are unknown, but are likely to involve several pathways. Impaired mitochondrial function (discussed above) leads to decreased axonal mitochondrial transport, 62, 113 which could result in defective transport of other cargoes because of the energy requirement of axonal transport. Tumor necrosis factor, which is elevated in mSOD1 mice, 114 disrupts kinesin function via a mechanism involving p38 mitogen-activated protein kinase (p38 MAPK), 115 activation of which has been demonstrated in models of ALS. 116, 117 Excitotoxic damage by glutamate is thought to contribute to motor neuron injury in ALS. In cultured neurons, glutamate reduces axonal transport of neurofilaments via activation of protein kinases that phosphorylate neuro filament proteins. 97, 118 Lastly, evidence suggests that damage to axonal transport cargoes might cause dysregulation of their binding to, or release from, molecular motors. For example, neurofilament transport is negatively regulated by phosphorylation, and p38 MAPK and cyclin-dependent kinase 5-two protein kinases that phosphorylate neurofilaments in vivo-are activated in ALS mouse models. 98, [117] [118] [119] Further support for the involvement of axonal transport defects and cytoskeletal dysfunction in ALS is provided by the identification of variants in the genes encoding microtubule-associated protein tau (which is associated with ALS, dementia and parkinsonism), 120 neurofilament heavy chain and peripherin in ALS cases. 121, 122 Evidence from both patients and disease models sup ports the concept that ALS is a dying-back axonopathy. 123, 124 Axonal transport defects are likely to contribute to the dying-back process, and in particular defects in anterograde axonal transport and mito chondrial dys function may combine to cause energy depletion specifical ly in the distal axon. 62 Neuroinflammation Activated microglia and infiltrating lymphocytes indicate an inflammatory component in the CNS pathology of ALS. 125 Proinflammatory mediators including monocyte chemoattractant protein 1 and IL-8 126 are present in the CSF of patients with ALS, and biochemical indices of immune-response activation are present in the blood. 127 Reduced counts of CD4 + CD25 + regulatory T (T REG ) cells and monocytes (CD14 + cells) are detected early in ALS, suggesting recruitment of these cells to the CNS early in the neurodegenerative process. T REG cells interact with CNS microglia, attenuating neuroinflammation by stimulating secretion of anti-inflammatory cyto kines. 128 Consistent with this scenario, double transgenic mice carrying mSOD1 and lacking CD4 develop a more aggressive ALS phenotype, which is reversible by bone marrow transplantation. 129 Neuroinflammation is closely linked to activation of the immune response. A recent study identified CD40L-a ligand expressed by T cells that activates the immune response when bound by CD40 on antigen-presenting cells-as a promising therapeutic target. Intraperitoneal injection of a CD40L-specific monoclonal antibody, MR1, in SOD1 G93A mice delayed the onset of disease, extended survival, and reduced CNS astrogliosis and microglial activation. 130 The reported activation of the complement system in both the mSOD1 mice 131, 132 and in human biosamples 133 may trigger an adaptive immune response, involving antigen-presenting cells, T cells and B cells, ultimately leading to inflammation.
Astrocyte activation plays a central part in inflammation, and mSOD1 astrocytes secrete inflammatory medi ators, including prostaglandin E2, leukotriene B4, and nitric oxide under both basal and activated conditions. 134 Moreover, co-cultures of human embryonic stem cell-derived motor neurons and either rodent or human astro cytes expressing mSOD1 showed motor neuron toxicity that could be ameliorated by inhibiting prostaglandin D2 receptors or NOX2. 135, 136 Taken together, these findings suggest that mSOD1 astrocytes are intrinsically more likely to enter an activated proinflammatory state than are their wild-type counterparts.
Endoplasmic reticulum stress Intracellular inclusions related to accumulation of misfolded or unfolded proteins are a pathological hallmark of ALS. Protein misfolding elicits the ER stress response pathway. The initial unfolded-protein response (UPR) 137 involves the recognition of aberrant proteins by ER-resident chaperones that correct protein folding. In addition, non-functional proteins can cause suppression of general translation and ER-associated protein degradation. 138 Although these mechanisms are initially cytoprotective, prolonged activation can trigger a poptotic signaling. 139 Several lines of evidence implicate ER stress as an early feature of motor neuron injury in ALS. Protein disulphide isomerase (PDI), an ER-resident chaperone and a marker of the UPR, is activated in mSOD1 mice, where it colocalizes with mSOD1 inclusions, 140 and in biosamples from patients with SALS. 141 PDI and other UPR-induced proteins are upregulated prior to disease onset in mSOD1 rodents, suggesting that ER stress is involved in the early stages of motor neuron injury. 141 Markers of ER stress are also upregulated in the CSF and spinal cord of patients with SALS. 141 In mSOD1 mice, gene expression profiles of motor neurons innervating fast fatigable fibers, which are vulnerable to disease, or fast fatigue-resistant and slow fibers, which are more resistant to the disease, indicated that vulnerable motor neurons displayed differential upregulation of several UPR markers, and this response preceded muscle denerva tion. 142 Similar changes eventually occurred in disease-resistant motor neurons after a delay of 25-30 days. 142 Nerve crush experiments showed that vulnerable motor neurons were selectively more prone than resistant motor neurons to UPR activation. 142 Exposure of NSC-34 cells and primary spinal motor neurons to CSF from patients with ALS leads to clear evidence of ER stress, including expression of UPR markers, ER fragmentation and caspase-12 activation. 143 The CSF constituents that are responsible for these changes have not yet been identified.
Although UPR activation is thought to be cytoprotective, at least in the initial phases of cellular stress, 139 a surprising increase in survival was observed in mSOD1 mice lacking a key UPR transcription factor, X-boxbinding protein 1, 144 accompanied by increased activation of ER-associated protein degradation, enhanced autophagy and decreased mSOD1 aggregation. 145 The protective role of autophagy in ALS is also supported by the evidence that CHMP2B mutations, which disrupt autophagy, are found in some ALS cases. 106, 107 Mutations in VAPB are a rare cause of FALS. 104 VAPB is a type II integral ER membrane protein involved in multiple cellular processes, including intracellular trafficking, lipid transport and the UPR. 146 Identified mutations result in conformational changes that lead to VAPB aggregation and increased ER stress. 147 Dysregulated transcription and RNA processing RNA processing was first implicated in motor neuron degeneration by the identification of mutations in SMN1 as a cause of spinal muscular atrophy. 148 The SMN protein functions in the assembly of small nuclear ribonucleoproteins, which are important for pre-mRNA splicing. 149 Gene expression profiling demonstrated transcriptional repression in NSC-34 cells stably expressing SOD1 G93A and in isolated motor neurons from SOD1 G93A mice with late-stage disease.
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Identification of TDP-43, a ubiquitously expressed RNA-DNA binding protein, as a major component of the ubiquitinated inclusions in ALS 7 focused attention on altered RNA processing as an important potential pathophysiological mechanism in this disease (Figure 3) . TDP-43 is a predominantly nuclear protein that is implicated in multiple aspects of RNA processing, including transcriptional regulation, alternative splicing and microRNA (miRNA) processing. TDP-43-positive cytoplasmic inclusions are present in both neuronal and glial cells in cases of ALS, although not in mSOD1-related or FUS-related ALS. 150 This difference may signify an alternative neurodegenerative cascade in these genetic subtypes of ALS. Mutations in TARDBP are responsible for 4% of FALS cases and 1.5% of SALS cases. 150 The majority of mutations reside in exon 6, which encodes the glycine-rich domain involved in protein-protein interactions and possibly also nuclear transport. Expression of mutant TDP-43 in cultured cells leads to a predominantly cytoplasmic localization of the protein, particularly in cytoplasmic stress granules. 151 FUS is an RNA-DNA-binding protein that is involved in transcriptional regulation, RNA and miRNA processing, and mRNA transport. The FUS gene is mutated in 4% of FALS cases and less than 1% of SALS cases. 150 Most mutations are located in exons 13-15, which encode the RGG-rich region and the nuclear localization signal. These mutations disrupt the transportin-mediated nuclear localization of FUS, and induce the formation of FUS-containing cytoplasmic stress granules. 152, 153 Whether motor neuron injury is caused by loss of normal nuclear functions of TDP-43 and FUS in RNA pro cessing (Figure 3) , or by toxic gains of function, or both is unknown. TDP-43 and FUS contain two RNA recog nition domains-structures that are common to many RNA-interacting proteins, including those that are involved in mRNA transport. TDP-43 and FUS may form part of such RNA transport complexes and, when mutated, could thereby contribute to motor neuron injury through loss of axonal mRNA transport. Alternatively, decreased nuclear expression and function of these proteins could disrupt various aspects of RNA processing, including pre-mRNA splicing, nuclear mRNA export, mRNA sorting to distinct cytoplasmic compartments, and/or processing of noncoding RNAs. Over 4,000 RNA-binding targets of TDP-43 have recently been identified. These targets include RNA transcripts of the neurodegeneration-related genes FUS, VCP and TARDBP, and are enriched for transcripts encoding proteins involved in RNA metabolism, synaptic function and CNS development. 154 The recognition motif (TG) 6 , which occurs in both exonic and intronic sequences, is enriched in TDP-43 targets. 154 Three recent studies using ultraviolet cross-linking and immunoprecipitation (CLIP) analysis applied to brain and spinal cord tissue from mouse models and humans have investigated the RNA-binding targets of TDP-43.
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The results have provided evidence for RNA splicing changes in CNS tissue that showed features of TDP-43-related proteinopathy or that lacked TDP-43. These reports demonstrate that TDP-43 binds to a multitude of target RNA molecules-approximately 30% of the mouse transcriptome. Binding occurs most commonly to long UG-rich sequences in introns, and less frequently to noncoding RNA molecules or to the 3' untranslated region of mRNA. The high proportion of intronic binding sites points to a nuclear function of TDP-43. Exceptionally long introns are prominent in transcripts from the brain, which might explain in part the neuronal vulnerability to loss of TDP-43 function. Blocking Tardbp43 expression with antisense oligonucleotides in adult mouse striatum altered the expression levels of 601 mRNA transcripts and changed the splicing patterns of 965 mRNA transcripts, including those corresponding to genes that are relevant to neurodegeneration, such as FUS, progranulin and choline acetyltransferase. 155 A further recent study indicates that mutant TDP-43 dysregulates alternative splicing of mRNA. 158 Fibroblast cell lines derived from patients with TARDBP-related ALS showed the expected loss of nuclear expression of TDP-43, together with widespread changes in RNA splic ing, including changes in transcripts of other RNAprocessing genes and genes that have been previously implicated in ALS. The authors concluded that splicing dysregulation associated with loss of nuclear TDP-43 is likely to contribute to the pathophysiology of ALS.
Several in vivo models of TDP-43 dysfunction, including knockout models and models overexpressing the wild-type and mutant forms of the protein, have recently been generated in mouse, rat, Drosophila melanogaster, zebrafish (Danio rerio) and Caenorhabditis elegans. A comprehensive account of these models is beyond the scope of this article, and is provided in two recent reviews. 159, 160 A note of caution relating to genetic studies is that although gene structures are often similar between species, intronic sequences show great variability. Given the key role of TDP-43 in binding to long intronic sequences, the intraspecies variability in introns may hinder accurate modeling of human TDP-43 proteino pathies in other species, including rodents. 157 Further evidence of dysfunctional RNA metabolism in ALS emerges from the presence of mutations in angiogenin (ANG) 161 and the DNA-RNA helicase senataxin (SETX) in some cases. ANG, the expression of which is increased during hypoxia to promote angiogenesis, also acts as a transfer RNA-specific ribonuclease and regulates ribosomal RNA transcription. 162 A proposed mechanism by which ANG normally prevents cell death is inhibition of the translocation of apoptosis-inducing factor into the nucleus. 163 Mutations in ANG are likely to have a deleterious effect through loss of function, as overexpression of ANG extends the lifespan of mSOD1 mice. 162 SETX autosomal dominant mutations are associated with juvenile-onset FALS. 164 The SETX protein is predicted to be a component of large ribonucleoprotein complexes, with roles in maintaining DNA repair in response to oxidative stress, and RNA processing. 164 The mechanisms by which mutant SETX causes ALS remain to be determined.
Additional evidence that dysregulated RNA process ing may contribute to motor neuron injury in ALS arises from the detection of biomarkers of RNA oxidation in human ALS and mSOD1 mice, 34 and the transcriptional repression within motor neurons that occurs in the presence of mSOD1.
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The role of non-neuronal cells An important recent concept is that motor neuron death in ALS is a non-cell-autonomous process, in which neigh boring glial cells have a crucial role. In chimeric mice expressing mSOD1 in specific cell types, normal motor neurons developed signs of ALS pathology when surrounded by mSOD1-expressing glia. 165 The proportion of non-neuronal cells that lacked the transgene correlated positively with the proportion of surviving mSOD1-expressing motor neurons and the lifespan of the chimeric mice.
To determine the contribution of astrocytes and microglia to this finding, double transgenic mice were generated expressing the Cre-Lox recombination system to exclude mSOD1 from motor neurons or cells of the myeloid lineage. 166 A note of caution about this experimental approach is that the time point at which Cre-Lox recombination becomes effective in these models is not known. Transgenic mice in which the mutant allele, encoding SOD1 G37R , had been deleted from motor neurons showed delayed disease onset, but no alteration in the disease course once it had been initiated. When mSOD1 was eliminated from microglia, disease onset was not altered, but disease progression was slowed by nearly 50%. Thus, the onset of the disease and its subsequent progression and propagation are likely to represent two separate phases of disease, highlighting distinct possibilities for therapeutic intervention.
Although targeted expression of mSOD1 in astrocytes fails to produce an ALS phenotype, 167 selective silencing of the mutant gene in astrocytes substantially slows disease progression in mSOD1 mice. 168 Rodent primary astrocytes expressing mSOD1 have toxic effects on cultured primary motor neurons and both embryonic mouse and human stem cell-derived motor neurons. 135, 169 This finding indicates that astrocytes expressing mSOD1 exert toxic effects or are unable to provide the required trophic support for motor neurons.
Conflicting results were obtained when targeted expression of mSOD1 was limited to motor neurons in murine models. 170, 171 The amount of SOD1 expressed seems to be crucial in triggering motor neuron injury and disease onset. Mice lacking the SOD1 G37R mutation in oligodendrocytes show a more aggressive disease course than do mice in which oligo dendrocytes express mSOD1, and this phenotype is accompanied by reduced expression of the neurotrophic factor insulin-like growth factor 1. 172 Expression of SOD1 G93A exclusively in Schwann cells does not lead to motor neuron pathology, and increasing mSOD1 expression in Schwann cells does not exacerbate the disease phenotype. 173 Thus, although mSOD1 expression in oligodendrocytes and Schwann cells alters the properties of these cells, it does not seem to be sufficient to cause motor neuron degeneration.
A better understanding of the crosstalk between glia and motor neurons should inform therapeutic efforts to ameliorate motor neuron injury in ALS. Towards this goal, a recent study examined how astrocyte properties change in the presence of mSOD1 and contribute to motor neuron degeneration. 174 Reduced metabolic support from lactate release and activation of the pronerve growth factor-p75 receptor signaling pathway were identified as key components of astrocyte toxicity to motor neurons. Elimination of the astrocyte toxicity could be achieved by increasing lactate provision to motor neurons, depleting NGF levels, or blocking the p75 receptor.
Motor neuron vulnerability
The selective vulnerability of particular neuronal groups to the neurodegenerative process is a key feature of ALS and other neurodegenerative disorders. The reason why motor neurons are particularly susceptible to injury in the presence of mutations that affect ubiquitously distributed proteins, such as SOD1 and TDP-43, is not completely understood. The cell-specific features of motor neurons that may predispose these cells to age-related degeneration have been reviewed elsewhere 175, 176 and are summarized in Box 3.
Important properties are likely to include the large cell size, including long axons and large terminal arbors. This feature has implications for intracellular transport, energy metabolism and the requirement for mito chondrial and cytoskeletal support, as well as the regulation of mRNA distribution for protein synthesis. The neurons that are vulnerable to injury in ALS have particular sensitivity to glutamatergic toxicity via AMPA receptor activation. These neurons, unlike most other neuronal groups, have high expression levels of calcium-permeable AMPA receptors that lack the GluR2 subunit, 69 and low levels of cytosolic calcium-buffering proteins. 70 Vulnerable motor neurons also seem to have a high threshold for mounting a protective heat shock response, 176 increased sensitivity to ER stress, 142 and mitochondrial features that predispose the cells to oxidative damage and calcium overload. 177, 178 Emerging evidence suggests that motor neurons that are more resistant to the disease process, such as fast fatigue-resistant motor neurons in the spinal cord and the oculomotor neurons in the brainstem, differ from the vulnerable spinal cord motor neurons in some of these key properties. 69, 70, 175, 176 In SOD1-related ALS in humans, the motor neurons that survive the disease process show upregulation of genes that promote cell survival-namely, those encoding the phosphatidylinositol 3-kinase and the phosphatase and tensin homolog-protein kinase B pathway. 12 Increased understanding of the properties of neurons that are more resistant to the disease process in ALS is likely to uncover strategies to boost intrinsic neuroprotective defense mechanisms.
From molecular to clinical features
In this section, we discuss four striking aspects of the clini cal phenotype that are relevant to the patho physiological mechanisms described above. Appreciating such links between mechanistic and clinical findings could lead to improved therapeutic strategies for ALS.
Muscle cramps and fasciculations
Muscle cramps, which can precede other symptoms by years, and fasciculations (visible spontaneous contractions of motor units) are prominent clinical features of ALS. They may result from increased excitatory drive to motor neurons caused by dysregulation of gluta matergic neurotransmission, reduced inhibitory interneuronal mechanisms or persistent inward Na + conductance in motor axons. 179 Age of disease onset A noteworthy clinical feature of FALS is that although the mutant protein has been present throughout life, the disease only manifests after several decades. This feature implies that the motor system can initially compensate for the cellular stress caused by the mutant protein but, with age, the homeostatic mechanisms become overwhelmed and irreversible motor neuron damage ensues. Several important changes occur in the aging CNS, including deterioration of mitochondrial function, antioxidant defense, key signaling pathways and astrocyte properties. 180 An important avenue of future investigation will be to identify the effects of aging on motor neurons and glia, which may help in developing therapeutic strategies to boost intrinsic neuroprotective mechanisms that were effective for many years prior to disease onset.
Spread of disease ALS often starts focally and asymmetrically in the upper limb, lower limb or bulbar territories, with progressive spread of injury to contiguous groups of motor neurons, such that the clinical features often show an anatomically 'logical' progression. This pattern of spread implies that motor neuron injury propagates from an initial nidus of pathology to neighboring, healthy neurons. As discussed above, glia may have an important role in the propagation of motor neuron injury. In addition, CSF from patients with ALS patients is toxic to cultured motor neurons, at least under some experimental conditions, 181 and so might also play a part in the spread of disease. These mechanistic findings relating to glia and the CSF highlight potential therapeutic targets to interrupt disease propagation, which represents an important area of future research.
Energy metabolism
The contribution of mitochondrial dysfunction and oxidative stress to motor neuron degeneration are likely to converge and cause neuronal energy depletion, perhaps affecting the distal axon most severely. Several features of dysregulation of energy metabolism, including a hypermetabolic profile, hyperlipidemia and weight loss, are found in patients with ALS, which may reflect an attempt to compensate for failing mitochondrial energy generation within the motor system. 182 
Conclusions
The mechanisms of motor neuron degeneration in ALS are complex and multifactorial. Mutations in at least 15 genes can cause FALS, and the genetic basis of 70% of FALS cases remains to be found. We are still in the early stages of understanding the genetic and environmental causes of SALS. Much of our current understanding of disease biology has come from studying the subtype of ALS associated with mutations in SOD1, in which a complex interplay between multiple patho physiological mechanisms culminates in motor neuron injury (Figure 1 ). SOD1-related FALS does not seem to cause TDP-43 proteinopathy, indicating that the pathophysiological mechanisms in this subtype of ALS are different from those in other subtypes. The relative importance of different pathways will vary according to the subgroup of the patient, and a crucial task for the future is to subclassify ALS more accurately, which will improve prognostic prediction and therapeutic targeting. Interestingly, a recent report has reopened the possibility of a viral contribution to SALS, 183 with the finding that transcripts of a human endogenous retrovirus (HERV-K) polymerase are increased in the brains of patients with ALS compared with several control groups. Further work is required to replicate these results and confirm their specificity for SALS.
The identification of TDP-43 as a major constituent of the cytoplasmic inclusions that are found in most patients with ALS has been a major step towards connecting postmortem pathology with pathophysiological mechanisms. Further research is needed to determine why ubiquitinated inclusions containing mutated TDP-43 and FUS are ■ Greater vulnerability to toxicity in the presence of mutant SOD1
found in SALS and FALS patients without mutations in the corresponding genes, and how these alterations link to motor neuron injury. Therapies aimed at preventing the dying-back axonopathy and improving glial support for motor neurons are likely to be important avenues for future therapeutic endeavor. For some newly discovered genes associated with ALS, such as those encoding spatacsin 184 and the σ non-opioid intracellular receptor 1, 185, 186 the molecular mechanisms of motor neuron injury will be unraveled as the normal functions of these proteins become better understood.
Note added in proof
An intronic expansion in the gene called chromosome 9 open reading frame 72 has recently been identified as the underlying cause of 9p21-linked SALS and FALS, 196, 197 which are discussed in the 'Genetic factors' section of this article.
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